Market Access Issues Hindering Specialists’ Use of Advanced Systemics in Lupus Nephritis
July 27, 2023 16:00 ET
|
Spherix Global Insights
Exton, Pennsylvania, July 27, 2023 (GLOBE NEWSWIRE) -- While the approvals of GSK’s Benlysta (belimumab) and Aurinia’s Lupkynis (voclosporin) have provided rheumatologists and nephrologists with...
Akebia’s Vafseo (vadadustat) Poised to Make Waves for GSK’s Jesduvroq and FibroGen/Astellas’ Evrenzo
July 20, 2023 15:07 ET
|
Spherix Global Insights
Exton, Pennsylvania, July 20, 2023 (GLOBE NEWSWIRE) -- Nephrologists have long awaited the approval of HIF-PH inhibitors for the treatment of anemia in their chronic kidney disease (CKD) patients....
A Call for Help from Physician Specialists on the Frontline Treating MASLD/MASH
July 18, 2023 09:29 ET
|
Spherix Global Insights
Exton, Pennsylvania, July 18, 2023 (GLOBE NEWSWIRE) -- Data from the Centers for Disease Control & Prevention (CDC) suggests just over seventy percent of American adults are overweight,...
Pfizer’s Litfulo Poised to Follow Similar Trajectory as Eli Lilly/Incyte’s Olumiant for the Treatment of Severe Alopecia Areata
July 11, 2023 09:58 ET
|
Spherix Global Insights
Exton, Pennsylvania, July 11, 2023 (GLOBE NEWSWIRE) -- In June 2022, Eli Lilly and Incyte’s Olumiant became the first and only approved advanced systemic treatment for adults with severe alopecia...
Despite Impressive Early Uptake of Apellis’ Syfovre in Geographic Atrophy, US Ophthalmologists Struggle to Articulate the Complement Inhibitor’s Value Proposition to Potential Patients
June 28, 2023 13:32 ET
|
Spherix Global Insights
Exton, Pennsylvania, June 28, 2023 (GLOBE NEWSWIRE) -- With the U.S. FDA approval of Apellis’ Syfovre (pegcetacoplan) on February 17th, 2023 for the treatment of geographic atrophy (GA), patients...
Nearly One Year Post-Launch Biogen & Coherus Biosciences’ Ranibizumab Biosimilars Have Yet to Make a Splash in Their Respective Retina Markets
June 23, 2023 11:41 ET
|
Spherix Global Insights
Exton, Pennsylvania, June 23, 2023 (GLOBE NEWSWIRE) -- Spherix has been tracking ophthalmologists’ attitudes and perceptions around biosimilars in their Special Topix: Ophthalmology Biosimilars...
Patients with Moderate-to-Severe SLE are Increasingly Being Treated with Biologic Therapies Such as GSK’s Benlysta and AstraZeneca’s Saphnelo, According to Spherix Global Insights
June 15, 2023 15:16 ET
|
Spherix Global Insights
Exton, PA, June 15, 2023 (GLOBE NEWSWIRE) -- Systemic lupus erythematosus (SLE) patients present significant challenges in management, given the complexity of the condition and few effective...